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The generation of large numbers of functional human
hepatocytes for cell-based approaches to liver dis-
ease is an important and unmet goal. Direct reprog-
ramming of fibroblasts to hepatic lineages could
offer a solution to this problem but so far has only
been achieved with mouse cells. Here, we generated
human induced hepatocytes (hiHeps) from fibro-
blasts by lentiviral expression of FOXA3, HNF1A,
and HNF4A. hiHeps express hepatic gene programs,
can be expanded in vitro, and display functions
characteristic of mature hepatocytes, including
cytochrome P450 enzyme activity and biliary drug
clearance. Upon transplantation into mice with
concanavalin-A-induced acute liver failure and fatal
metabolic liver disease due to fumarylacetoacetate
dehydrolase (Fah) deficiency, hiHeps restore the liver
function and prolong survival. Collectively, our re-
sults demonstrate successful lineage conversion of
nonhepatic human cells into mature hepatocytes
with potential for biomedical and pharmaceutical
applications.
INTRODUCTION
Overexpression of lineage-specific transcription factors has
been broadly used to change cell fates (Vierbuchen and Wernig,
2011; Yamanaka and Blau, 2010). Direct cell lineage conversion
through reprogramming facilitates the generation of donor or-
gan-independent cells for applications in regenerative medicine
or personalized disease modeling (Cherry and Daley, 2012; Tis-
cornia et al., 2011; Vierbuchen and Wernig, 2011). Whereas370 Cell Stem Cell 14, 370–384, March 6, 2014 ª2014 Elsevier Inc.several studies have successfully converted mouse fibroblasts
into other cell types, it is well accepted that human cells are resis-
tant to lineage reprogramming (Nam et al., 2013; Pang et al.,
2011; Qiang et al., 2011). Transdifferentiation into neuronal cells
(iN) has been demonstrated in human cells; however, the in vivo
functions of human iN, especially their application in therapeutic
treatment, have not yet been thoroughly characterized (Pang
et al., 2011; Qiang et al., 2011). A recent studymanaged to repro-
gram human fibroblasts into cells with a cardiac fate, but these
cells lackedmature cardiac functions (Nam et al., 2013). Further-
more, transdifferentiated cells are proliferation arrested, which
precludes them from expanding in large numbers for in vivomea-
surements and biomedical applications (Graf and Enver, 2009).
The liver is a pivotal organ in regulating many physiological
processes, such as glycogen storage, lipid metabolism, plasma
protein secretion, and xenobiotic detoxification (Hengstler et al.,
2005). Liver diseases, such as liver metabolic diseases and
fulminant liver failure, are important causes of death worldwide.
Liver transplantation is currently the only curative treatment for
these diseases at the end stages. Primary human hepatocyte
(PHH) transplantation has been recently evaluated in clinics as
an alternative to organ transplantation (Dhawan et al., 2010).
On the other hand, liver support devices containing functional
hepatocytes have been developed in order to allow the liver to
recover from acute liver failure (Carpentier et al., 2009). Besides
the therapeutic applications, hepatocytes are widely used for
diseasemodeling, such as hepatitis C virus infection and human-
ized animal models, and for drug metabolism and pharmacoki-
netics analysis, e.g., hepatobiliary disposition of drug candidates
(Azuma et al., 2007; Go´mez-Lecho´n et al., 2004; La´zaro et al.,
2007). However, the demand for liver organs and functional
hepatocytes far exceeds the supply of cadaveric livers and liver
tissues from living donors. Generation of surrogate hepatocytes
is the key to meeting these demands.
We and others have previously demonstrated that mouse
fibroblasts could be directly converted to hepatic lineage by
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Human Hepatocytes Generated by Lineage Conversiondefined transcription factors (Huang et al., 2011; Sekiya and
Suzuki, 2011). The extension of these findings to human cells
is a challenge that must be overcome for biomedical and phar-
maceutical applications (Cherry and Daley, 2012; Tiscornia
et al., 2011; Vierbuchen and Wernig, 2011). Here, we report the
efficient generation of human-induced hepatocytes (hiHeps)
from human fetal fibroblasts (HFFs), adult fibroblasts (HAFs),
and adult adipose tissue-derived mesenchymal stem cells (AD-
MSC) by FOXA3, HNF1A, and HNF4A, which differ from factors
used for mouse cells. hiHeps show mature hepatic functions,
specifically, cytochrome P450 (CYP) enzyme activities and
biliary excretion of drug compounds. Notably, we demonstrate
the therapeutic effects of hiHeps on fumarylacetoacetate hydro-
lase (Fah)-deficiency-induced metabolic liver disease and
concanavalin A (Con A)-induced acute liver failure. These results
indicate that hiHeps could be applied in cellular therapies, dis-
ease modeling, and drug discovery.
RESULTS
Generation of hiHeps by Direct Lineage Conversion
Mouse fibroblasts have been converted into induced hepato-
cytes (iHeps) (Huang et al., 2011; Sekiya and Suzuki, 2011). In
this study, wewished to induce functionally mature human iHeps
(hiHeps). We first generated primary human fetal limb fibroblasts
(HFF1) and demonstrated that HFF1 cells were free of fetal
hepatoblasts (Figures S1A and S1B available online). Based on
findings in mouse cells (Huang et al., 2011), lentiviruses carrying
human FOXA3, HNF1A, and GATA4 were introduced into HFF1
cells. However, the expression of hepatic genes was not induced
as measured by quantitative PCR (qPCR) (Figure S1C), suggest-
ing that a different protocol is required for hepatic conversion in
human cells.
We therefore designed a de novo screen for factors critical
for hiHep induction. We selected eight human transcription
factors (8TF; Figure 1A; Table S1), including pioneer factors
FOXA3 and GATA4 (Zaret and Carroll, 2011), liver-enriched
transcription factors HNF1B, HNF4A, HHEX, PROX1, C/EBPb
(Zaret, 2008; Zaret and Grompe, 2008), and KLF4, a transcrip-
tion factor important for mesenchymal-to-epithelial transition in
reprogramming (Li et al., 2010). The mRNA levels of hepato-
cyte-specific genes, such as Albumin (ALB), Cytokeratin 18
(CK18), Transthyretin (TTR), and Transferrin, were markedly
induced in HFF1 after the expression of 8TF (Figure S1D).
Upon removing single factors, we found that FOXA3, HNF1B,
and HNF4A were important for hepatic conversion (Figures
S1E–S1J). Interestingly, replacement of HNF1B with HNF1AFigure 1. Induction of Hepatocytes from Human Fetal Fibroblasts
(A) Experimental design for the induction of human hepatocytes (hiHeps). Pr
hepatic transcription factors (Table S1). The culture medium was changed to HM
induction.
(B) FOXA3, HNF1A, and HNF4A induced hepatic gene expression in human fetal
expression as measured by quantitative PCR (qPCR). Data are normalized to 3T
(C) hiHeps show typical epithelial morphology.
(D) Gradually increased hepatic gene expression during the induction of hiHeps. T
normalized to HFF+3TF at day 4.
(E) Genes specific to the original fibroblasts were silenced in hiHeps at 2 weeks aft
as controls in (D) and (E).
Scale bars, 100 mm. Data are represented as the mean ± SD. See also Figure S1
372 Cell Stem Cell 14, 370–384, March 6, 2014 ª2014 Elsevier Inc.dramatically enhanced ALB expression (Figure S1K). Removing
individual factors from FOXA3, HNF1A, and HNF4A (collectively
referred to as 3TF) reduced the expression of hepatic genes
(Figure 1B). Notably, 3TF induced higher levels of hepatic
gene expression than did other combinations of transcription
factors (Figure S1L). 3TF also triggered increased H3K9
acetylation at the promoter region of ALB and AAT genes, sug-
gesting an epigenetic remodeling during hepatic conversion
(Figure S1M). Based on these three factors, we improved hiHep
induction by optimizing the culture conditions for fibroblasts,
fibroblast seeding density, virus infection, and hepatocyte
culture medium (see the Supplemental Experimental Proce-
dures; Table S2).
hiHeps induced with 3TF displayed an epithelial morphology
at 12 days after induction (Figure 1C). The expression of
genes specific for mature hepatocytes, e.g., ALB, ASGPR1,
and Transferrin, increased gradually during hiHep induction,
suggesting that hepatic conversion is a progressively coordi-
nated process (Figure 1D). By contrast, the expression of
fibroblast-specific genes was dramatically reduced in hiHeps
(Figure 1E).
hiHeps Possess Gene Expression Pattern and Functions
Specific for Mature Hepatocytes
Approximately 20% of cells expressed both ALB and a-1-anti-
trypsin (AAT) at day 12 as determined by immunofluorescent
staining and flow cytometry (Figures 2A and 2B), suggesting an
efficient conversion. Moreover, hiHeps showed a remarkable
capability for secreting the plasma proteins ALB and AAT at
the level close to primary human hepatocytes as measured by
ELISA (Figures 2C and 2D).
Genome-wide expression profile analysis revealed that
hiHeps were clustered closely with cultured PHH (Figure 2E).
Expression profiling also showed the fibrotic genes were effi-
ciently silenced in hepatic conversion, which was in line with
the published expression profiles of induced pluripotent stem
cells (iPSCs) (Sridharan et al., 2009; Stadtfeld et al., 2008).
Gene set enrichment analysis (GSEA) showed that pathways
enriched in PHHs were significantly enriched in hiHeps, in-
cluding those involved in lipid metabolism, amino acid meta-
bolism, and phase I and phase II detoxification (Figure S2; Table
S3). These data indicate that HFFs undergo hepatic conversion
by transcriptional alterations at the whole-genome level. In
agreement with the systemic expression of hepatic genes,
hiHeps displayed numerous hallmark functions of mature hepa-
tocytes, such as glycogen storage (Figure 2F), acetylated low-
density lipoprotein (ac-LDL) intake (Figure 2G), indocyanineimary human fibroblasts were infected with lentiviruses expressing human
M medium 2 days after infection. hiHeps were characterized 10–14 days after
limb fibroblasts (HFF1). Withdrawal of individual factors reduced hepatic gene
F.
he expression levels of the indicated genes were analyzed by qPCR. Data are
er induction. Data are normalized to HFF1. PHHs cultured for 2 days were used
and Tables S1 and S2.
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Figure 2. hiHeps Acquire Hepatic Gene Expression Pattern and Mature Functions
(A) Coexpression of the mature hepatic proteins ALB and AAT was determined by immunofluorescent staining.
(B) hiHeps were stained for albumin (ALB) and a-1-antitrypsin (AAT) at 2 weeks after induction. ALB and AAT double-positive cells, as quantified by flow
cytometry, were used to determine the conversion efficiency of hiHep. PHHs cultured for 2 days were used as positive controls.
(C and D) Excretion of ALB (C) and AAT (D) increased during hepatic conversion as measured by ELISA.
(E) Gene expression profile analysis of HFFs, PHHs, unsorted hiHeps, and HepG2 cells by cDNA microarray. Hierarchical clustering shows that hiHeps are
grouped together with primary human hepatocytes (PHH). PHH were cultured for the indicated number of days. PHH cultured at day 2 were grouped closely to
PHH at day 6, suggesting that PHHmaintain gene expression at a relatively stable level after cultured for 2 or more days. Human hepatoblastoma cell line HepG2
(legend continued on next page)
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Human Hepatocytes Generated by Lineage Conversiongreen (ICG) absorption (Figure 2H), and cytoplasmic accumula-
tion of neutral triglycerides and lipids (Figure 2I).
Hepatic lineage conversion induced by 3TF was confirmed in
an additional HFF cell line, HFF2 (Figures 3A–3D). Furthermore,
to exclude the possibility of hepatoblast contamination in fetal
cell preparations, we demonstrated that hiHeps could be derived
from CD133EpCAM fibroblasts (Figure S3).
Additionally, we characterized hepatic conversion from human
adult dermal fibroblasts (HAFs). Morphologic change and
hepatic gene expression were induced by 3TF in HAFs (Figures
3E and 3F). HAF-derived hiHeps showed hepatic functions,
such as glycogen accumulation and ac-LDL intake (Figures 3G
and 3H). Intriguingly, less than 10% of the cells were positive
for both ALB andAAT (Figure 3I), suggesting that hepatic conver-
sion from HAFs is less efficient than that from HFFs.
Detoxification and Biliary Excretion of hiHeps
Cytochrome P450 (CYP450) enzymes of hepatocytes are major
enzymes accounting for drug detoxification. Their activities and
responses to specific inducers are irreplaceably used to assess
drug metabolism and drug-drug interaction in pharmacology
(Guengerich, 2002). Intriguingly, phase I and phase II drug meta-
bolic genes were enriched in both PHH cells and hiHeps (Fig-
ure S2; Table S3).
We next analyzed whether hiHeps were responsive to CYP
inducers. Before addition of chemical inducers, hiHeps already
expressed several CYP450 enzymes at remarkable levels (Fig-
ure 4A). Transcriptional activation of CYP450 enzymes and
many other drug metabolism enzymes are mediated by nuclear
receptors, including AHR, CAR, and PXR (Liddle and Goodwin,
2002). These nuclear receptors were highly expressed in hiHeps
as determined by qPCR (Figure 4B). Furthermore, 3-methylcho-
lanthrene, phenobarbital, or rifampicin treatment markedly
induced mRNA expression levels of CYP1A2 (an AHR target
gene), CYP2A6 (a CAR target gene), CYP2B6, CYP2C8, and
CYP2C9 (target genes of CAR and PXR). CYP3A4, which is a
target gene of CAR and PXR, was induced at a relatively low
but significant level by phenobarbital (Figure 4C). Importantly,
in another assay for CYP activities, hiHeps showed CYP
enzyme-dependent metabolism of phenacetin, coumarin, and
dextromethorphan (Figure 4D).
Membrane transporter-mediated biliary excretion is another
important function of hepatocytes for clearance of xeno-
biotics. Drug clearance through biliary excretion is a critically
evaluated property in the selection of drug candidates (Liu
et al., 1999; Pan et al., 2012). Significant efforts have been
made to identify surrogate in vitro models to evaluate biliary
excretion (Liu et al., 1999; Pan et al., 2012). We found that
the expression levels of key transporter genes were signifi-
cantly expressed in hiHeps (Figure 4E). Importantly, hiHepswas included to reveal that the expression patter of hiHeps is closer to that of PH
colors.
(F) Glycogen storage by hiHeps was confirmed by periodic acid-Schiff (PAS) sta
(G) Intake of acetylated low density lipoprotein labeled with the fluorescent probe
LDL) in hiHeps (red).
(H) Indocyanine green (ICG) uptake in hiHeps (green).
(I) Lipid accumulation in hiHeps as shown by oil red O staining.
Scale bars, 100 mm. Data are represented as the mean ± SD. See also Figure S2
374 Cell Stem Cell 14, 370–384, March 6, 2014 ª2014 Elsevier Inc.showed remarkable biliary excretion indices (BEI) for the
clearance of multiple efflux transporter substrates, such as
[D-Pen2,5]-enkephalin hydrate (DPDPE), D8-taurocholic acid
(D8-TCA), and cholyl-lysyl-fluorescein (CLF) (Figure 4F), sug-
gesting a potential application for hiHeps in the assessment
of drug biliary clearance. Together, our data indicate that
hiHeps possess remarkable mature hepatic phenotypes and
functions.
Expansion of Functional hiHeps by SV40 Large TAntigen
For in vivo functional characterization, it is necessary to expand
hiHeps in large numbers. However, hiHeps derived from
both HFFs and HAFs were proliferation arrested (Figure 5A),
likely caused by reduced expression of Cyclin A and B
(Figure S4A). After employing several strategies, we found
that the Lentivirus-mediated expression of SV40 large T antigen
(LT) allowed hiHeps to proliferate with restored expression of
Cyclin A and B (Figure 5A; Figure S4B). hiHeps with LT expres-
sion (hiHepLT) exhibited typical epithelial cell morphology
(Figure 5B) and expressed mature hepatic genes at the levels
comparable to those in hiHeps, e.g., ASGPR1 and Transferrin
(Figures 5B and 5C). Expression profile analysis revealed
that hiHepLT cells were clustered together with hiHeps and
PHH (Figure 5D). Moreover, hiHepLT cells acquired mature
hepatic functions, including glycogen accumulation, ac-LDL
absorption, ALB secretion, CYP metabolism, and biliary excre-
tion (Figures 5E–5J). Compared with hiHeps, hiHepLT cells
showed similar biliary excretion functions, whereas albumin
secretion and CYP activities were attenuated (Figures 5G–5J).
Remarkably, hiHepLT cells maintained constant levels of
hepatic gene expression and functions after several passages
(Figures 5C–5F). Similarly, hiHepLT cells were successfully
induced from HAFs (Figures S4C–S4E). Furthermore, we
generated hiHeps from adipose tissue-derived mesenchymal
stem cells (AD-MSC), which are readily available from patients.
hiHeps derived from AD-MSCs possessed comparable he-
patic functions to those of fibroblast-derived hiHeps (Figures
S4F–S4J).
hiHeps Are Stably Converted Mature Hepatocytes but
Not Hepatic Progenitor Cells
Notably, exogenous FOXA3, HNF1A, and HNF4A were silenced
in expandable hiHeps (Figure S5A), whereas endogenous fac-
tors were markedly induced (Figure S5B). These data suggest
stable conversion of hiHeps to a hepatic fate. Although
hiHepLT cells were proliferating cells, hepatoblast marker genes,
including EpCAM, DLK1, LGR5, and CYP3A7, were undetect-
able or expressed at low levels (Figures S5C and S5D). A low
level of a-fetoprotein (AFP) mRNA was detected in hiHepLT,
which is slightly higher than that observed in human liver cellsH as indicated by the cluster tree on the top. Expression levels are depicted in
ining (magenta).
1,10-dioctadecyl-3,3,30,30-tetramethyl- indocarbocyanine perchlorate (DiI-ac-
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Figure 3. Generation of hiHeps from Human Fetal and Adult Fibroblasts
(A) hiHeps derived from another fetal fibroblast line, HFF2, by FOXA3, HNF1A, and HNF4A overexpression exhibited epithelial-like morphology.
(B) HFF2-derived hiHeps expressed hepatic genes as determined by qPCR. PHHs cultured for 2 days were used as controls. Data are normalized to HFF2-hiHep.
(C and D) HFF2-derived hiHeps exhibited hepatic functions, including glycogen storage, as determined by PAS staining (C) and ac-LDL intake (D).
(E) hiHeps derived from human adult fibroblasts (HAFs) exhibited epithelial-like morphology.
(F) Hepatic gene expression induced by 3TF in HAF-derived hiHeps as measured by qPCR. PHHs cultured for 2 days were used as controls. Data are normalized
to HAF-hiHep.
(G and H) HAF-derived hiHeps exhibited hepatic functions, including glycogen storage, as determined by PAS staining (G) and ac-LDL intake (H).
(I) Twelve days after hepatic induction in HAFs, 10% of the cells expressed both ALB and AAT as determined by immunofluorescent staining.
Scale bars, 100 mm. Data are represented as the mean ± SD. See also Figure S3.
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Figure 4. hiHeps Possess CYP Enzyme Activities and Biliary Excretion Capability
(A–C) For themeasurement of Cytochrome P450 (CYP) enzyme expression and induction, hiHeps and PHHswere cultured for 48 hr and then changed tomedium
supplemented with or without chemical inducers for additional 48 hr.
(A) The mRNA levels of CYP genes were determined by qPCR in PHHs and hiHeps cultured for 2 days before inducer treatment. Data are normalized to PHH.
(B) Expression levels of detoxification-related nuclear receptors were measured by qPCR in hiHep, and PHH cells were cultured for the same duration as in (A).
Data are normalized to PHH.
(C) The mRNA levels of the induced CYP enzymes were measured by qPCR. CYP1A2 was induced by 3-methylcholanthrene. CYP2A6, CYP2C8, and CYP2C9
were induced by rifampicin. CYP2B6 and CYP3A4 were induced by phenobarbital. Fold induction in hiHep and PHH cells were normalized to the levels in cells
without inducer treatment, respectively.
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Human Hepatocytes Generated by Lineage Conversion(Figure S5E). The AFP protein level in hiHepLT cells was unde-
tectable by immunofluorescent staining (Figure S5F). Further-
more, hepatoblast marker genes, including TBX3 and SOX9,
were not induced during the early stage of hepatic lineage
conversion (Figure S5G). Importantly, biliary epithelium marker
genes were not expressed in hiHepLT cells, and hiHepLT cells
did not develop bile duct tubes in a three-dimensional culture
(Figures S5H and S5I). These results largely exclude the exis-
tence of bipotential hepatic progenitors in hiHeps. Taken
together, our results indicate that hiHeps are mature hepato-
cytes, but not hepatoblasts.
hiHep Transplantation Improves Fah-Deficiency-
Induced Liver Metabolic Disease
The expansion of hiHepLT cells in large numbers allowed the
measurement of hepatic functions in vivo. We transplanted
hiHepLT cells into fumarylacetoacetate hydrolase-deficient
(Fah/) mice (Azuma et al., 2007; Overturf et al., 1996). Fah/
mice were maintained with 2-(2-nitro-4-trifluoro- methylben-
zyol)-1,3-cyclohexanedione (NTBC) supply and died of liver
failure within 4–6 weeks after NTBC withdrawal (Azuma et al.,
2007; Overturf et al., 1996). Wild-type hepatocytes can repopu-
late the liver and rescue Fah/mice after intrasplenic transplan-
tation, thus providing a useful model to characterize the in vivo
function of hiHeps.
To reduce the immunological response to human cells,
Fah/Rag2/ (F/R) mice lacking mature T and B cells were
additionally treated with antibodies against mouse asialo-GM1,
which depleted NK-cells, and the immunosuppressive drug
FK506 (Figure 6A) (He et al., 2010). F/R mice that did not receive
transplanted cells and those that were transplanted with HFF
cells lost their body weights and died approximately 4 weeks
after removing the supply of NTBC (Figure 6B), whereas trans-
plantation with PHH extended the life of F/R mice (Figure 6B, 3
of 8 mice survived). Notably, 5 of 15 recipient mice survived
9 weeks after transplantation with hiHepLT cells (Figure 6B).
The mice transplanted with PHH and hiHepLT cells lost their
body weights during the first 3 weeks but regained or stabilized
their body weights in the rest period of the experiment (Fig-
ure S6A). Serum levels of ALT and AST were significantly
reduced in the surviving recipients (Figures 6C and 6D), suggest-
ing that the liver functions improved. Human ALB was also
detected in the sera of mice transplanted with hiHepLT cells
(Figure 6E).
Immunohistochemical staining of human Fah and AAT showed
that hiHepLT cells repopulated 0.3%–4.2% of the liver paren-
chyma in the surviving mice (Figures 6F, S6B, and S6C). Repo-
pulated Fah-positive cells were positively stained by HepPar-1,
an antibody specifically labeling human hepatocytes, but not
mouse hepatocytes or nonhepatic cells (Figure S6D). Engraft-
ment of hiHepLT cells in recipient livers was further confirmed
by genomic PCR for human-specific Alu DNA sequences (Fig-(D) CYPmetabolic activity in hiHeps. CYP enzymes were induced in hiHeps for 48
control. The metabolic products of phenacetin (acetaminophen, assay for CYP1
dextromethorphan (dextrorphan, assay for CYP2D6 activities) were determined
(E) Expression of drug transporter genes in hiHeps as determined by qPCR. Dat
(F) hiHeps show the capability for biliary excretion as measured by clearance o
cholyl-lysyl-fluorescein (CLF). Sandwich cultured PHH were used as positive con
Cure 6G). Notably, hiHeps did not fuse with mouse hepato-
cytes as determined by immunofluorescent staining using
antibodies specifically against FAH and mouse Albumin (Fig-
ure S6E). Repopulated hiHepLT cells were microdissected for
analysis of human hepatic gene expression. Compared with
cultured hiHepLT cells, the mRNA levels of human ALB and
AAT were attenuated in repopulated hiHepLT cells, whereas
the expression of CYP3A4 was increased (Figure 6H). Remark-
ably, AFP levels were further reduced in repopulated hiHepLT
cells (Figure 6I), suggesting that the gene expression pattern of
hiHepLT is further remodeled by the in vivo microenvironment.
Together, our data suggest that hiHepLT cells can repopulate
F/R livers and ameliorate impaired liver functions caused by
Fah deficiency.
In this experimental setting, SV40 LT was merely employed
as a strategy to expand hiHeps for in vivo functional assays.
Nevertheless, we characterized the tumorigenicity of hiHepLT
cells. Intriguingly, tumors were not detected in recipient F/R
mice (data not shown). Repopulated hiHep nodules were not
proliferating as shown by Ki67 staining 9 weeks after transplan-
tation (Figure S6D), likely due to attenuated SV40 LT expression
in vivo (Figure S6F). Moreover, we found that hiHepLT cells
maintained normal chromosome numbers at late passages
(Figure S6G) and did not form tumors after transplantation in
immunodeficient mice (Figure S6H).
hiHeps Improve Con-A-Induced Fulminant Liver Failure
Encouraged by these results, we determined whether hiHeps
could have sufficient hepatic functions to support liver in
recovering from fulminant hepatitis. To that end, wild-type
mice were injected with concanavalin A (Con A) to trigger fulmi-
nate hepatitis and animal death within 12–24 hr (Figures 7A and
7B) (Tiegs et al., 1992). As an experimental model to demonstrate
hepatic functions of hiHeps, we encapsulated hiHepLT cells in
alginate-poly-L-lysine-alginate (APA)microcapsules (FigureS7A)
and intraperitoneally injected encapsulated cells into acute liver
failure mice (Figure 7A). Previous studies have shown that trans-
plantation of APA-encapsulated primary hepatocytes improved
the survival of animals with acute liver failure (Mei et al., 2009;
Roger et al., 1998; Wong and Chang, 1986). Semi-permeable
APA microcapsules isolate encapsulated cells from the immune
cells in the recipient but allow the exchange of molecules smaller
than 100 kDa (Orive et al., 2004; Wang et al., 2006; Xie et al.,
2011). As a confirmation of the semipermeability, human ALB
was readily detected in the serumof recipientmice after intraper-
itoneal transplantation of APA-encapsulated hiHepLT cells (Fig-
ures S7B).
Encapsulated cells were injected intraperitoneally into wild-
type mice 8 hr after Con A treatment (Figure 7A). In groups
transplanted with encapsulated HFFs and HepG2, almost all
recipients died within 24 hr after Con A treatment (one mouse
in the HFF group died at day 3, Figure 7B; Movie S1). PHHhr. Freshly thawed primary human hepatocytes were directly used as a positive
A2 activities), coumarin (7-hydroxycoumarin, assay for CYP2A activities), and
by liquid chromatography-tandem mass spectrometry. U.D., undetectable.
a are normalized to PHH.
f [D-Pen2,5]-enkephalin hydrate (DPDPE), D8-taurocholic acid (D8-TCA), and
trols. *p < 0.05, t test. Data are represented as the mean ± SD.
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Human Hepatocytes Generated by Lineage Conversiontreatment significantly improved the survival rate and extended
the survival time of mice with acute liver failure (Figure 7B). Mark-
edly, upon treatment with encapsulated hiHepLT cells, 5 of 14
mice completely recovered from Con-A-induced acute liver fail-
ure (Figure 7B; Movie S2) and showed normal serum ALT and
AST levels 4 days after Con A treatment (Figures 7C, 7D, and
S7C). It is worth noting that HepG2 cells have been used in
previous models of bioartificial liver-supporting devices; how-
ever, HepG2 cells showed no therapeutic effect on acute liver
failure in mice, suggesting that hiHeps may hold promise for
the development of the next generation of bioartificial liver-
supporting devices. Histological analysis revealed that en-
capsulated hiHepLT cells significantly improved recovery from
Con-A-induced liver damage (Figures 7E and 7F). Together,
these results reveal the hepatic functions of hiHeps in vivo and
provide evidence for the therapeutic effect of hiHeps in the treat-
ment of liver injuries, such as metabolic liver disease and acute
liver failure.
DISCUSSION
Here, we have generated functionally mature human hepato-
cytes directly from fibroblasts. Consistent with previous studies
on lineage conversion, our results show that human cells are
resistant to reprogramming, and multiple optimizations were
applied to develop a strategy for efficient hiHep induction (see
the Supplemental Experimental Procedures; Table S2). hiHeps
were induced by a set of factors: FOXA3, HNF1A, and
HNF4A. Intriguingly, it is known that HNF4A activates the
HNF1A promoter (Kuo et al., 1992), and Hnf4a alone with
Foxa1, 2, or 3 are sufficient to induce mouse iHeps (Sekiya
and Suzuki, 2011). However, additional expression of HNF1A
is necessary for conversion of human fibroblasts. This may be
partially explained by the fact that the transcriptional binding
sites and regulation differ in human and mouse liver cells
(Odom et al., 2007), despite the fact that these factors are
essential for hepatic gene expression in both human and mouse
cells (Zaret and Carroll, 2011). We also found that the removal of
C/EBPb and GATA4 enhanced hepatic gene expression. During
the induction of hiHeps, the exogenous transcription factors
trigger a dynamic change of cell identity. This process is
different from the static cell identity of mature hepatocytes or
liver development. It is likely that during hepatic conversionFigure 5. Expanding hiHeps
(A) hiHeps are proliferation arrested. Knockdown of p53, p21, or Rb had minima
hiHeps with proliferative capability. HFF1 cells were transduced with SV40 large
version (hiHepLT).
(B) Expandable hiHepLT cells displayed typical epithelial morphology and expre
nostaining of ALB and AAT (top panel) and ASGPR1 and ZO-1 (bottom panel).
(C) hiHepLT at early (passage 3) and late (passage 10) passages show similar expre
were used as controls. Data are normalized to PHH.
(D) Whole-genome expression analysis shows that the expression pattern of hi
(PHH).
(E–G) hiHepLT cells at early and late passages show comparable glycogen accu
(H) CYP metabolic activities of hiHepLTcells at passage 10. The products of phen
tandem mass spectrometry. The products of dextromethorphan metabolism we
(I) A qPCR assay shows that hiHepLT cells express high levels of drug transporte
(J) hiHepLT cells at passage 10 show a biliary excretion capability comparable to
Scale bars, 100 mm. Data are represented as the mean ± SD. See also Figures S
Cthe specific combination of transcription factors form a regula-
tory network distinctive from that in hepatocytes. It is thus
possible that the roles of C/EBPb and GATA4 in hepatic conver-
sion are dependent on the specific combination of factors used
for hiHep induction.
Proliferation arrest is a major hurdle for the application of
terminally differentiated cells generated by forced lineage
change (Graf and Enver, 2009). We previously used p19Arf
inactivation to expand mouse iHeps (Huang et al., 2011), which
was insufficient for human cells. This is likely due to the differ-
ence between the two species, because the inactivation of p53
alone was able to immortalize mouse fibroblasts (Harvey et al.,
1993; Tsukada et al., 1993) but was not enough to enhance
proliferation of human cells in vitro (Kiyono et al., 1998; Shay
et al., 1991). We found that LT expression enabled hiHeps to
proliferate. ALB- and AAT-expressing cell numbers were in-
creased in hiHepLT cells, likely resulting from continuous line-
age conversion during proliferation of these cells (Hanna
et al., 2009). hiHepLT cells provided us the opportunity to defin-
itively demonstrate the therapeutic effects of hiHeps on
metabolic liver disease and acute liver failure. Moreover, repo-
pulation of hiHeps in Fah-deficient mice presents a strategy for
development of humanized animal models for biomedical
research. Intriguingly, hiHepLT cells appeared to be nontumori-
genic, partially due to attenuated SV40 LT levels in hiHepLT
cells after transplantation in mice. Also, this observation is in
line with previous findings that SV40 LT alone is not sufficient
to induce tumorigenesis in mammalian cells (Land et al.,
1983). Although the expression of LT in hiHeps is not a concern
for in vitro disease modeling and application in extracorporeal
bioartificial liver-supporting devices (Carpentier et al., 2009), a
controllable LT expression system or other safe measures to
expand hiHeps should be developed for cell replacement
therapies.
Patient-derived hiHeps represent a type of functional hepato-
cytes that could be used in personalized regenerative medicine
and disease modeling. This is an advantage unmatchable by
HepG2 or other hepatic cell lines (Castell et al., 2006). Previous
studies have successfully generated hepatocytes from human
iPSCs (Ji et al., 2013). The derivations of hepatoctyes from iPSCs
or direct lineage conversion represent two valuable approaches
to obtain surrogate hepatocytes for disease modeling and ther-
apeutic applications.l effects on the proliferation of hiHeps; however, SV40 large T antigen endows
T antigen (HFF1+LT), followed by 3TF overexpression to induce hepatic con-
ssed hepatic proteins specific for mature hepatocytes as shown by coimmu-
ssion levels of hepatic genes as determined by qPCR. PHHs cultured for 2 days
HepLT cells is clustered with that of hiHeps and primary human hepatocytes
mulation (PAS staining) (E), DiI-ac-LDL intake (F), and ALB secretion (G).
acetin and coumarin metabolism were determined by liquid chromatography-
re not detected in hiHepLT cells.
r genes.
that of hiHeps.
4 and S5.
ell Stem Cell 14, 370–384, March 6, 2014 ª2014 Elsevier Inc. 379
AB
F
H I
G
C D E
Figure 6. The Therapeutic Effects of hiHeps on Metabolic Liver Diseases
(A) Schematic outline of hiHepLT cell transplantation into the livers of Fah/Rag2/ mice (F/R). NTBC was withdrawn from drinking water before cell trans-
plantation. F/R mice were pretreated with an antibody against asialo-GM1 1 day before cell transplantation to deplete natural killer cells. HFF1 (1 3 107 cells),
hiHepLT (13 107 cells), or PHH (13 106 cells) were intrasplenically transplanted into F/R mice. To reduce immunerejection of the donor cells, the recipient mice
were administered anti-mouse asialo-GM1 at 7 day intervals and were given the immunosuppressive drug FK506 daily. Animals were monitored daily and
sacrificed 9 weeks after transplantation.
(B) Kaplan-Meier survival curve of F/R mice that did not receive cells or received 13 107 HFF1 (HFF-F/R), hiHepLT (hiHepLT-F/R) or 13 106 PHH (PHH-F/R) after
NTBC withdrawal.
(C and D) Serum levels of ALT (C) and AST (D) in moribund control F/R mice (n = 3), surviving hiHepLT-F/R mice (n = 5), and surviving PHH-F/R mice (n = 3).
(E) Human ALB levels were determined by ELISA in the sera of surviving hiHepLT-F/R and PHH-F/R mice.
(legend continued on next page)
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Human Hepatocytes Generated by Lineage ConversionOur data show that hiHeps resemble PHH markedly in terms
of gene expression, hepatic functions, and therapeutic effects;
therefore, hiHeps have potential uses as surrogate hepato-
cytes in pharmaceutical research and cellular therapies (Ji
et al., 2013; Yu et al., 2012). For example, biliary excretion is a
key function of mature hepatocytes for the detoxification of
nondegradable xenobiotics (Pan et al., 2012). Because hiHeps
possess significant biliary excretion functions, it is possible
to apply these cells in evaluating biliary excretion of candidate
drugs.
It is remarkable that the repopulation of hiHeps rescued
around 30% of Fah-deficient mice. Previous studies have shown
that transplantation of primary mouse hepatocytes usually leads
to a survival rate close to 100% (Huang et al., 2011), whereas a
survival rate of 30%–50% is commonly observed after transplan-
tation of human primary hepatocytes (He et al., 2010). Interest-
ingly, the serum albumin level in hiHep-transplanted mice was
only 1/20–1/30 of that in PHH-transplanted mice when normal-
ized to the repopulation efficiency. Therefore, it is plausible
that there may be therapeutic effects of hiHeps or primary hepa-
tocytes other than secretion of Albumin. Nevertheless, the
function of hiHeps needs further improvement in order to obtain
better therapeutic effect or to generate humanized animal
models. On the other hand, because encapsulated hiHeps
show the capability to treat acute liver failure mice, it would
be of great interest to determine whether hiHeps could be
used as source cells for extracorporeal bioartificial liver-support-
ing devices in the future (Palakkan et al., 2013).
EXPERIMENTAL PROCEDURES
Detailed Experimental Procedures are provided in the Supplemental Experi-
mental Procedures.
Lentivirus Production
Modified pWPI plasmids carrying candidate genes were introduced into 293FT
cells together with packaging plasmid psPAX2 (Addgene) and envelop
plasmid pMD2.G (Addgene) to produce viruses.
hiHep Induction and Cell Culture
Human fibroblasts were seeded on a collagen-I-coated dish and infected with
lentiviruses carrying the indicated genes. Human fetal fibroblasts (HFFs) and
human adult fibroblasts (HAFs) were cultured in human fibroblast medium
(HFM). HFF1 and HFF2 were derived from limbs of human fetuses. HAFs
were derived from human skin biopsy. Primary human hepatocytes were
purchased from Invitrogen GIBCO or Celsis In Vitro Technologies. Institutional
ethical committees approved collection and use of human samples.
Human Albumin and a-1-Antitrypsin ELISA
Human Albumin and a-1 Antitrypsin were measured by the human Albumin
ELISA Quantitation Set (Bethyl Laboratory) and the human a-1-Antitrypsin
ELISA kit (Bethyl Laboratory).
Microarray Analysis
Total RNAs were hybridized to whole-human gene expression microarray
(Agilent) in accordance with the manufacturer’s instruction. Data were normal-(F) The integration of hiHepLT cells in F/R livers was determined by immunostain
(G) Human-specific Alu sequences were analyzed by PCR using genomic DNA e
(H and I) Fah-positive hiHepLT cells were collected by laser-capture microdisse
measured in hiHepLT-repopulated nodules (hiHepLT repopulated) and in culture
hiHepLT cells (H). mRNA levels of AFP are normalized to that in HepG2 cells (I).
* p < 0.05, log rank test for (B) and t test for (C)–(E). Scale bars, 100 mm. Data ar
Cized using Gene-Spring (Agilent). Original data are available in the NCBI Gene
Expression Omnibus (accession number GSE42643).
Assays for PAS, ac-LDL, ICG, and Oil Red O Staining
Cells were stained by Periodic-Acid-Schiff (PAS, Sigma-Aldrich) and DiI-ac-
LDL (Invitrogen). For indocyanine green (ICG, Sigma-Aldrich) uptake assay,
cells were changed medium with 1 mg/ml ICG and incubated at 37C for
1 hr, followed bywashingwith PBS three times. For oil redO staining, confluent
cells were stained by oil red O (Sigma-Aldrich).
CYP Metabolism Assay
For the measurement of CYP enzyme activities, cells were induced with
different compounds for certain drug metabolisms. The supernatants were
collected for measurement of metabolized compounds by liquid chromatog-
raphy-tandem mass spectrometry (LC-MS/MS; Agilent 1200 HPLC and ABI
4000 mass spectrometer).
Biliary Excretion Assay
Cells were incubated with test compound solution (DPDPE 5 mM, CLF 2.5 mM,
and D8-TCA 5 mM and diluted in Hank’s balanced salt solution [HBSS] buffer).
DPDPE and D8-TCA were analyzed by LC-MS/MS (LCMS-8030; Shimadzu).
The amount of CLF was quantified by measuring fluorescence at 492 and
536 nm with a Synergy 4 microplate reader (Biotek). Biliary excretion index
(BEI) was calculated as BEI = (AHBSS-AHBSS(Ca2+ free))/AHBSS 3 100%.
Transplantation of hiHepLT Cells into Fah-Deficient Mice
All animal experiments were performed in accordance with institutional regu-
lations. hiHepLT cells were intrasplenically transplanted into F/R mice after the
withdraw of NTBC water. Body weight was monitored twice a week posttrans-
plantation. Surviving recipient mice were sacrificed to collect blood and liver
samples 9 weeks after transplantation.
hiHepLT Cell Transplantation to Concanavalin-A-Induced Acute
Liver Failure Mice
C57Bl6/J mice were injected with concanavalin A (Sigma-Aldrich) at the dose
of 37.5 mg per kg body weight through tail vein. Encapsulated HFFs, hiHepLT
cells, or PHH were injected intraperitoneally into acute liver failure mice. Blood
samples were collected from surviving mice in a 24 hr interval. Liver samples
were collected after the surviving animals were sacrificed. All animal experi-
ments were performed in accordance with institutional animal regulations.
Statistics
For most statistic evaluation, unpaired Student’s t test was applied for calcu-
lating statistical probability in this study. For survival analysis, the Mantel-Cox
log rank test was applied. Statistic calculation was performed using Statistical
Program for Social Sciences software (SPSS, IBM). For all statistics, data from
at least three independent samples or repeated experiments were used.
ACCESSION NUMBERS
The microarray data reported in this paper has been deposited in the NCBI
GEO under accession number GSE42643.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, four tables(All PCR primers were provided in Table S4), and
two movies and can be found with this article online at http://dx.doi.org/10.
1016/j.stem.2014.01.003.ing for human Fah and AAT in serial sections.
xtracted from hiHepLT-repopulated F/R livers.
ction from serial liver sections. The mRNA levels of the indicated genes were
d hiHepLT cells (hiHepLT cultured) by qPCR. Data are normalized to cultured
e represented as the mean ± SD. See also Figure S6 and Table S4.
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